Bioventus (BVS) Liabilities and Shareholders Equity (2020 - 2026)

Bioventus (BVS) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $650.5 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 5.91% year-over-year to $650.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (down 8.0% YoY), and the FY2025 full-year result was $683.6 million, down 6.1% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $650.5 million, down from $683.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q4 2022 and bottomed at $650.5 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $794.2 million (2024), against an average of $884.7 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity jumped 113.51%; it then sank 41.98% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.4 billion in 2022, then tumbled by 40.92% to $810.9 million in 2023, then retreated by 10.23% to $728.0 million in 2024, then declined by 6.1% to $683.6 million in 2025, then fell by 4.83% to $650.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $650.5 million (Q1 2026), $683.6 million (Q4 2025), and $701.6 million (Q3 2025), per Business Quant data.

Peer Comparison